Showing 591-600 of 18560 results for "".
Addressing the Challenges of Influenza Vaccination on US College Campuses
https://reachmd.com/programs/everyday-family-medicine/addressing-the-challenges-of-influenza-vaccination-on-us-college-campuses/10005/Dr. Lisa Ipp explains why college students aren't getting flu shots and what health care officials can do to reverse this trend.Interstitial Pneumonia with Autoimmune Features (IPAF): A Research Classification
https://reachmd.com/programs/cme/interstitial-pneumonia-with-autoimmune-features-ipaf-a-research-classification/10943/Just what exactly is IPAF, and how can I help my patients?How Will Pharmacogenomics Play a Role in Diabetes Therapy?
https://reachmd.com/programs/diabetes-discourse/how-will-pharmacogenomics-play-a-role-in-diabetes-therapy/4879/Pharmacogenomics is applied to select medications with the goal of optimizing drug therapy: maximizing efficacy, minimizing toxicity, and minimizing pharmacokinetic and pharmacodynamic variability. Join guest host, Dr. Candis Morello and Dr. Joseph Ma, assistant professor of clinical pharmacy at theHow Your Words Will (or Won't) Instill Confidence in Your Patients
https://reachmd.com/programs/speaking-of/how-your-words-will-or-wont-instill-confidence-your-patients/7925/Imagine if you are a patient about to receive some difficult news. The doctor walks in and says "I think this is a temporary setback” or "I believe you’ll be okay.” How would you react to news presented in this way, and would you have confidence in your doctor's ability to see you through the healthGlycemic Control and Macrovascular Outcomes in Patients with Diabetes Using the Archimedes Model
https://reachmd.com/programs/diabetes-discourse/glycemic-control-and-macrovascular-outcomes-in-patients-with-diabetes-using-the-archimedes-model/5906/The assessment of intensive glycemic control in preventing cardiovascular disease is unclear. Discrepancies in recent clinical trials such as ACCORD, ADVANCE, PROactive and UKPDS 80 may reflect difference in study design and patients, versus glycemic control. How can using the Archimedes model illumKeeping an Eye on Macular Degeneration
https://reachmd.com/programs/revealing-retina/keeping-an-eye-on-macular-degeneration/2158/Dr. Roy Levit welcomes Dr. Julia Haller to The Revealing Retina. Dr. Haller is President of the American Society of Retina Specialists and Chairman, Wills Eye Hospital, Philadelphia. They will discuss the different types of macular degeneration, the demographics involved and who should be treating iExploring IGF1R as a New Therapeutic Target in Myasthenia Gravis
https://reachmd.com/programs/neurofrontiers/exploring-igf1r-as-a-new-therapeutic-target-in-myasthenia-gravis/35491/A recent study explored the potential roles of uric acid and the type 1 insulin-like growth factor receptor in the development and progression of myasthenia gravis (MG). Read about the findings and their implications for MG care.A Case of Missed Diagnosis, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
https://reachmd.com/programs/cme/a-case-of-missed-diagnosis-part-of-the-focused-sight-initiative-quality-improvement-interventions-in-retinal-disease/37713/Examine a case of misdiagnosed proliferative diabetic retinopathy, highlighting risk factors, imaging findings, and referral timing.The Road Ahead – Integrating Research Into Practice
https://reachmd.com/programs/cme/The-Road-Ahead-Integrating-Research-Into-Practice/35973/Catch up on the latest information on the management of macular telangiectasia type 2 (MacTel) with a new encapsulated cell therapy, revakinagene taroretcel.The Role of PARP Inhibitors in Metastatic Breast Cancer
https://reachmd.com/programs/project-oncology/the-role-of-parp-inhibitors-in-metastatic-breast-cancer/15820/PARP inhibitors are a type of targeted therapy used in the treatment of MBC by blocking the activity of an enzyme. Read more.